PARP1 inhibition in Trop2-driven NEPC significantly reduces NE function, tumor growth, and metastatic colonization in vivo, suggesting that PARP1 inhibitors may be a promising therapeutic strategy for metastatic PC expressing high levels of Trop2 [129]. This evidence concerns the gene TACSTD2 and pachyonychia congenita.